Citation: Jing Wang, Liangang Zhuo, Peng Zhao, Wei Liao, Hongyuan Wei, Yuchuan Yang, Shuming Peng, Xia Yang. Screening for a ¹⁷⁷Lu-labeled CA19-9 monoclonal antibody via PET imaging for colorectal cancer therapy[J]. Chinese Chemical Letters, ;2022, 33(7): 3502-3506. doi: 10.1016/j.cclet.2022.03.056 shu

Screening for a ¹⁷⁷Lu-labeled CA19-9 monoclonal antibody via PET imaging for colorectal cancer therapy

Jing Wang ^{a, b, c, *,} ,
Liangang Zhuo ^a ,
Peng Zhao ^a ,
Wei Liao ^a ,
Hongyuan Wei ^{a, d} ,
Yuchuan Yang ^a ,
Shuming Peng ^{a, *,} ,
Xia Yang ^{a, b, c, *,}

a.
Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang 621900, China
b.
NHC Key Laboratory of Nuclear Technology Mediccal Trasnformation (Mianyang Central Hospital), Mianyang 621900, China
c.
Key Laboratory of Nuclear Medicine and Molecular Imaging of Sichuan Province, Mianyang 621999, China
d.
Department of Nuclear Medicine, The Affiliated Hospital Southwest of Medical University, Luzhou 646000, China

wangjing_es@caep.cn

pengshuming@caep.cn

yangxia.youka@caep.cn

Received Date: 18 December 2021
Revised Date: 10 March 2022
Accepted Date: 14 March 2022
Available Online: 17 March 2022

Figures(4)

Carbohydrate antigen 19-9 (CA19-9) with multi epitopes relatively high expresses on colorectal cancer (CRC) cells, making it an attractive target for developing radioimmunotherapy (RIT) for CRC. The lutetium-177 (¹⁷⁷Lu) labeled monoclonal antibodies (mAbs) can selectively bind the corresponding antigens and release targeted cytotoxic radiation, which could induce cell apoptosis and reduce the drug-induced resistance. Here, a series of CA19-9 mAbs were labeled with zirconium-89 (⁸⁹Zr), and one with high tumor uptake was screened via PET imaging, which has potential application for the diagnosis of CRC. Then the screened mAb (C003) labeled with ¹⁷⁷Lu was utilized for CA19-9 targeted RIT, which presents a significant suppression effect on the growth of colo205 xenografts than immunotherapy alone. Meanwhile, the side effects of ¹⁷⁷Lu-DOTA-C003 are limited according to the results of in vivo study. Both ⁸⁹Zr-DFO-C003 for CRC immune-PET imaging and ¹⁷⁷Lu-DOTA-C003 for RIT against CRC exhibit good potential in clinical applications.
- Lutetium-177,
- CA19-9,
- Monoclonal antibody,
- Colorectal cancer,
- Radioimmunotherapy
1. [1]
  Colorectal Cancer Awareness Month 2021, Available online: https://www.iarc.who.int/news-events/colorectal-cancer-awareness-month-2021/. [Accessed November 11, 2021]
2. [2]
  Cancer Stat Facts: Colorectal Cancer, Available online: https://seer.cancer.gov/statfacts/html/colorect.html. [Accessed November 11, 2021]
3. [3]
  L.H. Biller, D. Schrag, JAMA 325 (2021) 669-685. doi: 10.1001/jama.2021.0106
4. [4]
  C.J. Kahi, C.R. Boland, J.A. Dominitz, et al., Gastroenterology 150 (2016) 758-768. e711. doi: 10.1053/j.gastro.2016.01.001
5. [5]
  S. Stintzing, F1000Prime Rep 6 (2014) 108. doi: 10.12703/P6-108
6. [6]
  M.D. Girgis, T. Olafsen, V. Kenanova, et al., Int. J. Mol. Imaging 2011 (2011) 834515. doi: 10.1155/2011/834515
7. [7]
  Z.N. Chen, L. Mi, J. Xu, et al., Int. J. Radiat. Oncol. Biol. Phys. 65 (2006) 435-444. doi: 10.1016/j.ijrobp.2005.12.034
8. [8]
  M.M. Andrade-Campos, A.E. Montes-Limón, G. Soro-Alcubierre, et al., Ann. Hematol. 93 (2014) 1985-1992. doi: 10.1007/s00277-014-2145-6
9. [9]
  D.L. Costantini, C. Chan, Z. Cai, et al., J. Nucl. Med. 48 (2007) 1357. doi: 10.2967/jnumed.106.037937
10. [10]
  S.V. Govindan, R. Stein, Z. Qu, et al., Breast Cancer Res. Treat. 84 (2004) 173-182. doi: 10.1023/B:BREA.0000018417.02580.ef
11. [11]
  F. Forrer, J. Chen, M. Fani, et al., Eur. J. Nucl. Med. Mol. Imaging 36 (2009) 1443-1452. doi: 10.1007/s00259-009-1120-2
12. [12]
  F.F. Guillermina, E.O. -G. Blanca, L.S.C. Clara, et al., Curr. Radiopharm. 8 (2015) 150-159. doi: 10.2174/1874471008666150313115423
13. [13]
  A. Vilchis-Juárez, G. Ferro-Flores, C. Santos-Cuevas, et al., J. Biomed. Nanotechnol. 10 (2014) 393-404. doi: 10.1166/jbn.2014.1721
14. [14]
  E.J. Razumienko, J.C. Chen, Z. Cai, et al., J. Nucl. Med. 57 (2016) 444-452. doi: 10.2967/jnumed.115.162339
15. [15]
  J.S. Batra, M.J. Niaz, Y.E. Whang, et al., Urol. Oncol. 38 (2020) 848. e849-848. e816.
16. [16]
  M.C. Yeh, B.W.C. Tse, N.L. Fletcher, et al., EJNMMI Res 10 (2020) 46. doi: 10.1186/s13550-020-00637-x
17. [17]
  M.K. Gupta, R. Arciaga, L. Bocci, et al., Cancer 56 (1985) 277-283. doi: 10.1002/1097-0142(19850715)56:2<277::AID-CNCR2820560213>3.0.CO;2-M
18. [18]
  R. Kannagi, M. Izawa, T. Koike, et al., Cancer Sci. 95 (2004) 377-384. doi: 10.1111/j.1349-7006.2004.tb03219.x
19. [19]
  H. Katoh, K. Yamashita, Y. Kokuba, et al., World J. Surg. 32 (2008) 1130-1137. doi: 10.1007/s00268-008-9535-7
20. [20]
  V. Liska, L. Holubec, Jr., V. Treska, et al., Anticancer Res. 27 (2007) 2861-2864. doi: 10.1016/j.schres.2009.05.024
21. [21]
  T.C. Mineo, V. Ambrogi, G. Tonini, et al., J. Am. Coll. Surg. 197 (2003) 386-391. doi: 10.1016/s1072-7515(03)00387-9
22. [22]
  W.S. Wang, J.K. Lin, T.J. Chiou, et al., Hepatogastroenterology 49 (2002) 160-164. doi: 10.1046/j.1523-5378.7.s1.2.x
23. [23]
  Y. Ikeda, M. Mori, A. Kido, et al., Am. J. Gastroenterol 86 (1991) 1163-1166. doi: 10.3109/00365529109003964
24. [24]
  X. Filella, R. Molina, J.J. Grau, et al., Ann. Surg. 216 (1992) 55-59. doi: 10.1097/00000658-199207000-00008
25. [25]
  W.M. Thomas, J.F. Robertson, M.R. Price, et al., Br. J. Cancer 63 (1991) 975-976. doi: 10.1038/bjc.1991.213
26. [26]
  L. Mare, A. Caretti, R. Albertini, et al., Inter. J. Biochem. Cell B 45 (2013) 792-797. doi: 10.1016/j.biocel.2013.01.004
27. [27]
  N. Dammes, D. Peer, Theranostics 10 (2020) 938-955. doi: 10.7150/thno.37443
28. [28]
  E. Dadachova, L.L. Chappell, M.W. Brechbiel, Nucl. Med. Biol. 26 (1999) 977-982. doi: 10.1016/S0969-8051(99)00054-2
29. [29]
  O.M. Ozpiskin, L. Zhang, J.J. Li, Theranostics 9 (2019) 1215-1231. doi: 10.7150/thno.32648
30. [30]
  A.K. Erdi, Y.E. Erdi, E.D. Yorke, et al., Phys. Med. Biol. 41 (1996) 2009-2026. doi: 10.1088/0031-9155/41/10/011
31. [31]
  S.M. Larson, J.A. Carrasquillo, N. -K.V. Cheung, et al., Nat. Rev. Cancer 15 (2015) 347-360. doi: 10.1038/nrc3925
32. [32]
  T.M. Allen, Nat. Rev. Cancer 2 (2002) 750-763. doi: 10.1038/nrc903
33. [33]
  E.J. Van Limbergen, D.K. De Ruysscher, V. Olivo Pimentel, et al., Br. J. Radiol. 90 (2017) 20170157. doi: 10.1259/bjr.20170157
34. [34]
  R.S.A. Goedegebuure, L.K. de Klerk, A.J. Bass, et al., Front. Immunol. 9 (2018) 3107. doi: 10.3389/fimmu.2018.03107
35. [35]
  M. Xu, Y. Han, G. Liu, et al., Mol. Pharm. 15 (2018) 4426-4433. doi: 10.1021/acs.molpharmaceut.8b00371
36. [36]
  J. Ren, M. Xu, J. Chen, et al., Theranostics 11 (2021) 304-315. doi: 10.7150/thno.45540
37. [37]
  J.A. Torok, J.K. Salama, Nat. Rev. Clinical Oncol. 16 (2019) 666-667. doi: 10.1038/s41571-019-0277-2
38. [38]
  A. Sabet, H. -. J. Biersack, S. Ezziddin, Semin. Nucl. Med. 46 (2016) 40-46. doi: 10.1053/j.semnuclmed.2015.09.005
1. [1]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
2. [2]
  Fan Zheng , Runsha Xiao , Shuai Huang , Zhikang Chen , Chen Lai , Anyao Bi , Heying Yao , Xueping Feng , Zihua Chen , Wenbin Zeng . Accurate visualization colorectal cancer by monitoring viscosity variations with a novel mitochondria-targeted fluorescent probe. Chinese Chemical Letters, 2025, 36(2): 109876-. doi: 10.1016/j.cclet.2024.109876
3. [3]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
4. [4]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
5. [5]
  Jia-Qi Feng , Xiang Tian , Rui-Ge Cao , Yong-Xiu Li , Wen-Long Liu , Rong Huang , Si-Yong Qin , Ai-Qing Zhang , Yin-Jia Cheng . An AIE-based theranostic nanoplatform for enhanced colorectal cancer therapy: Real-time tumor-tracking and chemical-enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109657-. doi: 10.1016/j.cclet.2024.109657
6. [6]
  Zhigang Zeng , Changzhou Liao , Lei Yu . Molecules for COVID-19 treatment. Chinese Chemical Letters, 2024, 35(7): 109349-. doi: 10.1016/j.cclet.2023.109349
7. [7]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
8. [8]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
9. [9]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
10. [10]
  Haijing Cui , Weihao Zhu , Chuning Yue , Ming Yang , Wenzhi Ren , Aiguo Wu . Recent progress of ultrasound-responsive titanium dioxide sonosensitizers in cancer treatment. Chinese Chemical Letters, 2024, 35(10): 109727-. doi: 10.1016/j.cclet.2024.109727
11. [11]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
12. [12]
  Xinyu You , Xin Zhang , Shican Jiang , Yiru Ye , Lin Gu , Hexun Zhou , Pandong Ma , Jamal Ftouni , Abhishek Dutta Chowdhury . Efficacy of Ca/ZSM-5 zeolites derived from precipitated calcium carbonate in the methanol-to-olefin process. Chinese Journal of Structural Chemistry, 2024, 43(4): 100265-100265. doi: 10.1016/j.cjsc.2024.100265
13. [13]
  Lan Yang , Yu Li , Mou Jiang , Rui Zhou , Hengjiang Cong , Minghui Yang , Lei Zhang , Shenhui Li , Yunhuang Yang , Maili Liu , Xin Zhou , Zhong-Xing Jiang , Shizhen Chen . Fluorinated [2]rotaxanes as sensitive ¹⁹F MRI agents: Threading for higher sensitivity. Chinese Chemical Letters, 2024, 35(10): 109512-. doi: 10.1016/j.cclet.2024.109512
14. [14]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
15. [15]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
16. [16]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
17. [17]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
18. [18]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
19. [19]
  Boran Cheng , Lei Cao , Chen Li , Fang-Yi Huo , Qian-Fang Meng , Ganglin Tong , Xuan Wu , Lin-Lin Bu , Lang Rao , Shubin Wang . Fluorine-doped carbon quantum dots with deep-red emission for hypochlorite determination and cancer cell imaging. Chinese Chemical Letters, 2024, 35(6): 108969-. doi: 10.1016/j.cclet.2023.108969
20. [20]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(409)
HTML views(13)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Screening for a 177Lu-labeled CA19-9 monoclonal antibody via PET imaging for colorectal cancer therapy

Metrics

通讯作者: 陈斌, bchen63@163.com

Screening for a ¹⁷⁷Lu-labeled CA19-9 monoclonal antibody via PET imaging for colorectal cancer therapy